- 作者：Young Jin Youn ; Jun-Won Lee ; Sung Gyun Ahn ; Seung-Hwan Lee ; Hyun Hee Choi ; Hyunmin Choi ; Cheol Ung Choi ; Jin Bae Lee ; Jang Hyun Cho ; Tae Soo Kang ; Byung Ryul Cho ; Kwang Soo Cha ; Moo Hyun Kim ; Min Su Hyon ; Sang-Sig Cheong ; Do-Sun Lim ; Kyoo Rok Han ; Myung Ho Jeong ; Keum Soo Park ; Junghan Yoon ; et al.
- 刊名：American Heart Journal
- 出版年：2013
- 出版时间：August, 2013
- 年：2013
- 卷：166
- 期：2
- 页码：224-229
- 全文大小：396 K
Background
The second-generation drug-eluting stents (DES) have shown superiority in many studies relating to safety and efficacy when compared with the first-generation DES. However, it is unclear whether there are differences in efficacy and safety among the second-generation DES after long-term follow-up.Methods
This multicenter, prospective, randomized, open-labeled trial will directly compare the efficacy and safety among the patients treated with either everolimus-eluting stent (EES), zotarolimus-eluting stent with biolinx polymer (ZES-R), or biolimus-eluting stent (BES) with minimal exclusion criteria. The primary end point is a patient-oriented composite consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically indicated target lesion revascularization at 24-month clinical follow-up post-index procedure. With the hypothesis that ¡°BES is non-inferior to EES¡± or ¡°BES is non-inferior to ZES-R¡± in primary end point, approximately 2,600 patients will be assigned to one of the types of stents using a web-based randomization system.
Conclusions
The CHOICE trial will directly compare the efficacy and safety of EES, ZES-R, and BES in everyday clinical practice for long-term follow-up.